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Abstract
Background: The aims of this study were to assess the prevalence of hepatitis C virus (HCV) infection in Japanese
patients with oral lichen planus and identify the impact of amino acid (aa) substitutions in the HCV core region
and IFN-sensitivity-determining region (ISDR) of nonstructural protein 5A (NS5A) associated with lichen planus.
Methods: In this retrospective study, 59 patients (group 1-A) with oral lichen planus among 226 consecutive patients
who visited our hospital and 85 individuals (group 1-B, controls) with normal oral mucosa were investigated for the
presence of liver disease and HCV infection. Risk factors for the presence of oral lichen planus were assessed by
logistic regression analysis. We compared aa substitutions in the HCV core region (70 and/or 91) and ISDR of NS5A of
12 patients with oral lichen planus (group 2-A) and 7 patients who did not have oral lichen planus (group 2-B)
among patients (high viral loads, genotype 1b) who received interferon (IFN) therapy in group1-A.
Results: The prevalence of anti-HCV and HCV RNA was 67.80% (40/59) and 59.32% (35/59), respectively, in group 1-
A and 31.76% (27/85) and 16.47% (14/85), respectively, in group 1-B. The prevalence of anti-HCV (P < 0.0001) and
HCV RNA (P < 0.0001) in group 1-A was significantly higher than those in group 1-B. According to multivariate
analysis, three factors - positivity for HCV RNA, low albumin level (< 4.0 g/dL), and history of smoking - were
associated with the development of oral lichen planus. The adjusted odds ratios for these three factors were 6.58,
3.53 and 2.58, respectively, and each was statistically significant. No significant differences in viral factors, such as aa
substitutions in the core region and ISDR of NS5A, were detected between the two groups (groups 2-A and -B).
Conclusion: We observed a high prevalence of HCV infection in patients with oral lichen planus. Longstanding
HCV infection, hypoalbuminemia, and smoking were significant risk factors for the presence of oral lichen planus in
patients. It is advisable for Japanese patients with lichen planus to be tested for HCV infection during medical
examination.
Background
H e p a t i t i sCv i r u s( H C V )i n f e c t i o ni sam a j o rp u b l i c
health problem because it causes chronic hepatitis, cir-
rhosis and hepatocellular carcinoma (HCC). In Japan,
elderly patients are at a higher risk for HCC and hepati-
tis C viral eradication has a smaller effect on hepatocar-
cinogenesis in older patients [1]. In Japan, refractory
cases with genotype 1b and high viral loads are seen in
as many as 70% of chronic hepatitis C patients.
Recent studies have identified both viral and host fac-
tors predictive of the outcome of interferon (IFN) ther-
apy. Among the viral factors, the number of
substitutions in the region amino acids (aa) 2209-2248
(IFN-sensitivity-determining region, ISDR, of nonstruc-
tural protein 5A, NS5A, in HCV genotype 1b) is asso-
ciated with a sustained virological response (SVR) after
IFN treatment of HCV genotype 1b patients [2,3]. In
addition, Akuta et al. reported that aa substitution at
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patients infected with HCV genotype 1b are indepen-
dent predictors of SVR and non-virological response
(NVR) [4,5] and also affect hepatocarcinogenesis [6].
HCV mainly affects the liver but there are several
extrahepatic manifestations of chronic HCV infection,
including hematologic diseases such as cryoglobulinemia
and lymphoma, renal disease such as membranoproli-
ferative glomerulonephritis, autoimmune disorders such
as thyroiditis, and dermatologic conditions such as
lichen planus and porphyria cutanea tarda [7-10].
Lichen planus is a chronic inflammatory disease that
affects the skin and oral mucosa. The association of
lichen planus with HCV infection has been reported
widely in the literature [11-16]. In particular, the relation-
ship between lichen planus and HCV has been suggested
by studies from Japan, Italy, Spain, and Brazil, indicating
a strong geographic relationship [11-16]. We first
reported a relationship between HCV and lichen planus
in Japan [12]. Previous reports indicated that there are no
differences in the viral factors such as viral load and gen-
otype between HCV-infected patients with lichen planus
and those without [17,18].
This study was conducted to determine the rate of
HCV infection in individuals with lichen planus, and
with normal oral mucosa as a control group, and to
investigate the impact of aa substitutions in the HCV
core region (70 and/or 91) and ISDR of NS5A among
HCV-infected patients with lichen planus and those
without.
Materials and methods
Group 1 (Patients)
A total of 226 consecutive patients had checkups for oral
mucosal diseases in the Digestive Diseases Center at
Kurume University Hospital Japan from February 2, 2010
to June 28, 2011. In this Digestive Diseases Center, physi-
cians, surgeons, radiologists and an oral surgeon examine
each patient in their own specialized area. An oral surgery
specialist diagnosed 59 of 226 patients with oral lichen pla-
nus clinically and/or histopathologically. These 59 patients
then consulted a liver specialist in the same center for the
presence or absence of liver disease. The 59 patients
(group 1-A) ranged in age from 32 to 87 years, with an
average age of 68.05 ± 9.93 years. There were 14 men and
45 women.
Group 1 (Controls)
We have continued carrying out health screenings of the
residents of X town (adult population: 7,389), in northern
Kyushu, Japan where the prevalence of HCV infection is
the highest in the country [19]. We reported previously
that the residents had a high prevalence of HCV infec-
tion, that HCV infection was the principal cause of liver
disorders, and that extrahepatic manifestations were
strongly associated with HCV infection [19-28].
In the previous study of 509 residents selected ran-
domly, the prevalence of antibodies to HCV (anti-HCV),
HCV RNA, and hepatitis B surface antigen (HBsAg) was
23.6%, 17.9%, and 2.6%, respectively [19]. We conducted
cohort studies from August 1990 to May 2002 on the
long-term prognosis of HCV carriers based on the same
subjects in the town and investigated the risk factors for
deaths due to HCC and liver cirrhosis [24,25].
One hundred and thirty nine subjects who had received
a liver disease examination in 2002 were interviewed in
person by two trained interviewers and all but one of
them were given an oral mucosal examination by an oral
surgeon. We used the headband fiber (50-100-10, Daiichi
Medical Co., Ltd.) that had a brightness of 34,000 luces for
mucosal examination. In this report, we used a control
group consisting of 85 age- and gender- matched indivi-
duals (group 1-B) with normal oral mucosa, selected from
the 139 subjects. The individuals ranged in age from 52 to
90 years, with an average age of 66.35 ± 9.83 years. We
inquired about the following information: present health
condition, medical treatment received in the hospital,
name of the family doctor, the kind of medicine taken,
and the presence of extrahepatic manifestations of HCV
infection such as diabetes mellitus and thyroid dysfunc-
tion. We also asked the family doctors of the subjects
about the presence of extrahepatic manifestations.
Group 2 (Patients)
The subjects were 19 patients with high titers of genotype
1b (over 100 KIU/mL or 5.0 log IU/mL) who were inves-
tigated for aa substitutions in the HCV core region (70
and/or 91) and ISDR of NS5A. These were non-SVR
patients among the 226 patients of group 1 who were not
able to eradicate an HCV during past IFN therapy. We
compared the characteristics of 12 patients who had
lichen planus (group 2-A) and 7 patients who did not
have lichen planus (group 2-B). Group 2 comprised 5
men and 14 women ranging in age from 44 to 73 years
(average 64.47 ± 8.48).
Methods
Serological assays
Serum samples from the 144 subjects, including 59
patients with lichen planus and 85 people with normal
oral mucosa, were tested for platelets (PLT) and hemo-
globin (Hb), and for the following liver function tests:
serum alanine aminotransferase (ALT), aspartate amino-
transferase (AST), lactate dehydrogenase (LDH), alkaline
phosphatase (ALP), total bilirubin (T.Bil), total choles-
terol (TC), total protein (TP), and albumin (Alb).
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Anti-HCV was measured using a chemiluminescent
enzyme immunoassay kit (Lumipulse II HCV, Fujirebio,
Tokyo, Japan). HCV RNA in serum was analyzed by the
Amplicor HCV test (Roche, Tokyo, Japan) up to December
6, 2007 and by quantitative PCR assay (COBAS AMPLI-
COR HCV MONITOR v 2.0 Test, COBAS AmpliPrep/
COBAS Taq-Man HCV Test, Roche Molecular Systems,
New Jersey, US) from December 7, 2007 [29,30]. HCV gen-
otype was determined by polymerase chain reaction assay,
using a mixture of primers for the subtype, as reported pre-
viously [31]. HBsAg was assayed using a chemiluminescent
immunoassay kit (Architect, HBsAg QT, Dainabot, Tokyo,
Japan). Ultrasonographic examination was performed on
59 patients and 27 control inhabitants infected with HCV
in order to investigate the shape of the liver and lesions
occupying the liver. Computed tomography and liver
biopsy were performed on some patients. We used other
possible predictors of liver cirrhosis progression, including
serum Alb, T.Bil, prothrombin time, and PLT.
Measurement of body weight
Obesity was defined as a body mass index (BMI) >
25 kg/m
2
Detection of amino acid substitutions in the core and
NS5A regions
Detection of aa substitutions in the HCV core region was
performed using the method reported previously [4,5] and
the patients were divided into two groups on the basis of
the findings. Patients with substitution of aa 70 in the core
region of HCV were assigned to the mutant type group
and patients without this substitution were assigned to the
wild type group. The ISDR of NS5A was analyzed using
the method reported previously [3]. Strains with no aa
changes in the ISDR, with 1 to 3 aa changes, and with > 3
aa changes were designated as wild type, intermediate
type, and mutant type, respectively.
Ethics considerations
The study protocol was approved by the Ethics Commit-
t e eo fK u r u m eU n i v e r s i t y( r e f e r e n c en u m b e r :2 1 3 4 - 1 )i n
accordance with the Declaration of Helsinki. Written
informed consent for participation in the study was
obtained from each patient.
Statistical analysis
All data are expressed as mean ± standard error. Differ-
ences between the two groups were analyzed using the
Mann-Whitney U test, Wilcoxon’s test, and the Fisher’s
exact test. Differences were judged significant for p <
0.05 (two-tailed). Adjusted odds ratios were calculated
using logistic regression analysis. All statistical analyses
were conducted using JMP Version 6 (SAS Institute,
Cary, NC, USA). The level of statistical significance was
defined as 0.05.
Results
Prevalence of HCV infection among patients with lichen
planus: a retrospective case-control study
We compared the characteristics of group 1-A and group
1-B. The characteristics of the 144 subjects studied are
shown in Table 1. The prevalence of anti-HCV and HCV
RNA was 67.80% (40/59) and 59.32% (35/59), respectively,
in group 1-A and 31.76% (27/85) and 16.47% (14/85),
respectively, in group 1-B. The prevalence of anti-HCV
(P < 0.0001) and HCV RNA (P < 0.0001) in group 1-A
was significantly higher than those in group 1-B.
T h ep r e v a l e n c eo fl i v e rd i s e a s e( P < 0.0001), thyroid
disease (P = 0.0440) and history of smoking (P =
0.0080) was significantly higher in group 1-A than in
group 1-B (Table 1).
The diagnosis of liver disease in group 1-A included:
past history of HCV infection (n = 1), chronic hepatitis C
(n = 20), chronic hepatitis C during IFN therapy (n = 4),
SVR after IFN therapy (n = 4), chronic hepatitis C with
autoimmune hepatitis (n = 1), chronic hepatitis C with
post-treatment of HCC (n = 2), HCV-related liver cirrho-
sis (n = 2), HCV-related liver cirrhosis with post-treatment
of HCC (n = 6), chronic hepatitis B (n = 1), HBV-related
liver cirrhosis B (n = 1), primary biliary cirrhosis (PBC)
(n = 1), fatty liver (n = 2), and fatty liver with alcoholic
liver disease (n = 1). Those of group 1-B included: past
history of HCV infection (n = 12), chronic hepatitis C (n =
11), SVR after IFN therapy (n = 1), chronic hepatitis C
with post-treatment of HCC (n = 1), HCV-related liver
cirrhosis (n = 1), and HCV-related liver cirrhosis with
post-treatment of HCC (n = 1).
We analyzed the differences between these two groups
in terms of laboratory values for liver function tests and
PLT. As shown in Table 1, abnormal levels of AST (P =
0.0009), ALT (P = 0.0031), Alb (P < 0.0001), T.Bil (P <
0.0001), TC (P = 0.0007), and PLT (P < 0.0001) differed
significantly between the groups.
We examined the viral load in 39 of 40 anti-HCV-
positive patients, excluding one patient who cleared
serum HCV RNA naturally (group 1-A). In seven
patients, including during IFN therapy (4 patients) and
SVR (3 of 4), the viral load was measured before IFN
therapy. The HCV RNA level was high viral load (over
100 KIU/mL or 5.0 log IU/mL) in 32 (82.05%) group 1-
A patients, low viral load (less than 100 KIU/mL or 5.0
log IU/mL) in 3 (7.69%) and unknown in 4 (10.26%). All
HCV RNA-positive individuals among 14 members of
g r o u p1 - Bh a dah i g hv i r a ll o a d .A sf o ra nS V Rc a s ei n
the group 1-B, pretreatment viral load was not clear.
We also examined the HCV genotype of group 1-A; the
genotype was 1b in 27 (77.14%) patients, 2a in two
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Characteristics Total Group1-A Group1-B A vs. B
with lichen
planus
with normal oral
mucosa
P
value
No. subjects 144 59 85
Sex male/female 39/105 14/45 25/60 NS
Age (mean ± SD), years 67.05 ± 9.87 68.05 ± 9.93 66.35 ± 9.83 NS
Liver disease positive (%) 73 50.69% 46 77.97% 27 31.76% <
0.0001
Diagnosis of liver
diseases
Past history of HCV
infection
13 9.03% 1 1.69% 12 14.12%
CH-C 31 21.53% 20 33.90% 11 12.94%
CH-C during IFN 4 2.78% 4 6.78% 0 0.00%
CH-C post IFN (SVR) 5 3.47% 4 6.78% 1 1.18%
CH-C + AIH 1 0.69% 1 1.69% 0 0.00%
CH-C + post HCV-related
HCC
3 2.08% 2 3.39% 1 1.18%
LC-C 3 2.08% 2 3.39% 1 1.18%
LC-C + post HCV-related
HCC
7 4.86% 6 10.17% 1 1.18%
CH-B 1 0.69% 1 1.69% 0 0.00%
LC-B 1 0.69% 1 1.69% 0 0.00%
PBC 1 0.69% 1 1.69% 0 0.00%
Fatty liver 2 1.39% 2 3.39% 0 0.00%
Fatty liver + ALD 1 0.69% 1 1.69% 0 0.00%
Normal liver 71 49.31% 13 22.03% 58 68.24%
Diabetes mellitus positive (%) 14 9.72% 6 10.17% 8 9.41% NS
Thyroid disease positive (%) 8 5.56% 6 10.17% 2 2.35% 0.0440
Extrahepatic malignant
tumor
positive (%) 15 10.42% 5 8.47% 10 11.76% NS
Smoking history yes (%) 37 25.69% 22 37.29% 15 17.65% 0.0080
History of alcohol intake yes (%) 59 40.97% 19 32.20% 40 47.06% NS
Anti-HCV positive (%) 67 46.53% 40 67.80% 27 31.76% <
0.0001
HCV RNA positive (%) 49 34.03% 35 59.32% 14 16.47% <
0.0001
HCV RNA level High 46 85.19% 32 82.05% 14 93.33% NS
Low 3 5.56% 3 7.69% 0 0.00% NS
unexmained 5 9.26% 4 10.26% 1 6.67%
HCV genotype 1b 27 55.10% 27 77.14% -
2a 2 4.08% 2 5.71% -
2b 0 0.00% 0 0.00% -
unexmained 20 40.82% 6 17.14% 14 100.00%
HBsAg positive (%) 3 2.08% 2 3.39% 1 1.18% NS
BMI 22.70 ± 3.20 22.44 ± 3.20 22.88 ± 3.20 NS
AST (U/L) (mean ± SD) 29.71 ± 16.86 36.09 ± 20.33 25.65 ± 12.78 0.0009
ALT (U/L) (mean ± SD) 25.47 ± 20.06 30.54 ± 22.39 22.25 ± 17.82 0.0031
LDH (U/L) (mean ± SD) 202.40 ±
43.56
211.42 ± 54.63 196.88 ± 34.34 NS
ALP (U/L) (mean ± SD) 272.76 ±
112.57
299.62 ± 155.99 256.33 ± 70.88 NS
TP (g/dL) (mean ± SD) 7.17 ± 0.42 7.27 ± 0.43 7.11 ± 0.41 NS
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group 1-B was not measured.
Multivariate analysis
In multivariable analysis, all variables in the univariable
analyses were included. According to multivariate analy-
sis, three factors, positivity for HCV RNA, low albumin
level (< 4.0 g/dL), and history of smoking, were asso-
ciated with the development of lichen planus. The
adjusted odds ratios for these three factors were 6.58,
3.53 and 2.58, respectively, and each was statistically sig-
nificant (Table 2).
Detection amino acid substitutions in the HCV core
region and ISDR of NS5A among HCV-infected patients
with lichen planus and those without
In the present study, aa substitutions in the core region
(70 and/or 91) and ISRR of NS5A were analyzed by
direct sequencing in 19 HCV-infected patients with
lichen planus and those without [3-5] (Table 3). No sig-
nificant differences were seen between the two groups
(groups 2-A and -B).
Discussion
In this study, we demonstrated that HCV infection is
significantly associated with the development of lichen
planus. The odds ratio was 6.58 (95% confidence inter-
val 2.89-15.69). This odds ratio was higher than that of
a meta-analysis published recently (odds ratio 2.8) [32].
Hypoalbuminemia and smoking also increased the risk
of lichen planus. However, substitutions of aa 70 and/or
91 and ISDR regions had no impact on the development
of lichen planus.
HCC is one of the most common malignancies, espe-
cially in Japan. The most important risk factors of HCC
are chronic hepatitis C, B and cirrhosis. The effect of Peg-
IFN and ribavirin (RBV) treatment on chronic HCV infec-
tion has been established in several controlled clinical stu-
dies [33]. The effects of IFN are summarized as follows:
elimination of HCV, reduction of hepatic inflammation,
improvement in liver fibrosis, and reduction in hepatocar-
cinogenesis [34]. In Japan, 70% of refractory cases are
infected with genotype 1b with a high HCV RNA load.
Japanese patients with chronic HCV infection are getting
older. Viral mutations leading to aa substitutions in the
HCV core region (70 and/or 91) and ISDR of NS5A have
been shown to be valuable as predictors of virological
response to combination therapy with Peg-IFN and RBV
[2-6]. In addition, single nucleotide polymorphisms (SNPs)
around the human interleukin 28B (IL28B) gene locus
have been reported to affect the efficacy of Peg-IFN and
RBV therapy in chronic hepatitis with HCV genotype 1b
infection [35,36]. In Japan, there is an established standard
therapy for chronic hepatitis C based on guidelines includ-
ing viral factors such as genotype and levels of HCV RNA.
More recently, the effects of variation of IL28B and aa sub-
stitutions in the HCV core region and ISDR of NS5A have
been established.
The association between lichen planus and HCV
infection seems to be more common in individuals liv-
ing in areas of Japan and Italy [11-13]. The difference in
the prevalence HCV-infection in patients with lichen
planus seems to be due to geographic differences in
HCV infection, selection of study subjects such as sex,
average age, and diagnosis in the respective countries,
and some genetic predisposition such as the HLA-DR6
Table 1 Characteristics of study population 1 (n = 144) (Continued)
Alb (g/dL) (mean ± SD) 4.15 ± 0.33 3.99 ± 0.38 4.26 ± 0.25 <
0.0001
T.Bil (mg/dL) (mean ± SD) 1.13 ± 5.27 2.03 ± 8.57 0.60 ± 0.20 <
0.0001
TC (mg/dL) (mean ± SD) 192.34 ±
35.28
179.12 ± 37.18 200.12 ± 31.84 0.0007
Hb (g/dL) (mean ± SD) 13.30 ± 1.39 13.16 ± 1.39 13.39 ± 1.38 NS
PLT (/μL) (mean ± SD) 18.30 ± 5.57 15.95 ± 6.42 19.71 ± 4.48 <
0.0001
HCV, hepatitis C virus; CH-C, chronic hepatitis C; LC-C, liver cirrhosis type C; HCC, hepatocellular carcinoma; CH-B, chronic hepatitis B; LC-B, liver cirrhosis type B;
AIH, autoimmune hepatitis; PBC, primary biliary cirrhosis; ALD, alcoholic liver disease; IFN, interferon; NS, not significant; AST, aspartate aminotransferase; ALT,
alanine aminotransferase; LDH, lactate dehydrogenase; ALP, alkaline phosphatase; TP, total protein; Alb, albumin; T.Bil, total bilirubin; TC, total cholesterol; PLT,
platelets
Table 2 Factors associated with lichen planus according to multivariate analysis
Adjusted odds ratio (95% confidence interval) P value
HCV RNA positive 6.58 (2.89 - 15.69) < 0.0001
Albumin < 4.0 g/dL 3.53 (1.42 - 9.05) 0.0072
History of smoking (yes) 2.58 (1.05 - 6.48) 0.0396
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more common in Italian patients with lichen planus and
HCV [37]. Moreover, not all reported studies included
screening of hepatic damage and measurement of serum
HCV RNA to determine the presence or absence of
hepatic diseases. The areas of our study are in the
northern Kyushu region, where the HCV infection rate
and the mortality rate from HCC are the highest in
Japan. Previous reports indicated that there are no dif-
ferences in the viral factors such as viral load and geno-
type between HCV-infected patients with lichen planus
and those without [17,18]. This study ruled out a direct
association of viral factors, such as substitutions of aa
70 and/or 91 and in the ISDR region, with the develop-
ment of HCV-related lichen planus.
We reported that the prevalence of HCV-related
lichen planus increased as the subjects grew older in
Japan [38]. We also reported previously the prevalence
of HCV infection among lichen planus among 45
patients who visited the Department of Oral Surgery at
our hospital from November 1993 to April 1994 [12].
The mean age (68.1 years) of the 59 patients (group 1-
A) in the present study was higher than that (61.1 years)
of the previous 45 patients.
We demonstrated a strong association between
hypoalbuminemia and mortality in a hyperendemic area
(X town) of HCV infection in Japan [39]. Residents with
hypoalbuminemia had a mortality of 68.0%; dramatically
higher than the rate of 12.1% among residents who had
normal albumin levels. Hypoalbuminemia was an inde-
pendent risk factor for the development of lichen pla-
nus. Recent studies have demonstrated the efficacy of
branched-chain amino acid (BCAA) supplementation in
improving hypoalbuminemia in cirrhotic patients [40].
The effects of BCAA intake have been investigated in a
number of disease models, including obesity and meta-
bolic disorders, liver disease, impaired immunity, muscle
atrophy, cancer, and a variety of injury (postoperative,
trauma, burn, and sepsis) [41]. Among Japan’sa g i n g
population, BCAA intake seems to be useful for HCV-
infected patients with lichen planus.
Conclusion
In conclusion, our data show that HCV infection could
be the main pathogenic factor of lichen planus in Japa-
nese patients. Routine HCV testing and medical exami-
nation for lichen planus are recommended for patients
in high-risk HCV areas like Japan. Further investigation
is required to clarify the mechanisms of development of
HCV-related lichen planus.
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HCV: Hepatitis C virus; CH-C: Chronic hepatitis C; CH-B: Chronic hepatitis B;
LC-C: Liver cirrhosis type C; LC-B: Liver cirrhosis type B; HCC: Hepatocellular
carcinoma; PBC: Primary biliary cirrhosis; IFN: Interferon; RBV: Ribavirin; SVR:
Sustained virological response; NVR: Non-virological response; aa: Amino
acids; ISDR: IFN-sensitivity-determining region; NS5A: Nonstructural protein
5A; PLT: Platelets; Hb: Hemoglobin; ALT: Alanine aminotransferase; AST:
Aspartate aminotransferase; LDH: Lactate dehydrogenase; ALP: Alkaline
Table 3 Characteristics of study population 2 (n = 19)
Characteristics Group2-A
with lichen planus
(n = 12)
Group2-AB
without lichen
planus (n = 7)
P
value
Age (mean ± SD), years 64.83 ± 7.51 63.86 ± 10.57 NS
Sex (male/female) 4/8 1/6 NS
Diagnosis of liver diseases CH-C (CH-C post HCC) 10 (2), 83.33% 7 (100%) NS
LC-C (LC-C post HCC) 2 (1), 16.67% 0 (0%) NS
Viral factors HCV RNA level (logIU/mL) High 12 (100%) 7 (100%) NS
HCV genotype 1b 12 (100%) 7 (100%) NS
Amino acid substitutions in
the core region
aa 70 (wild type/non-wild) 5/7 (41.67%/
58.33%)
2/5 (28.57%/71.43%) NS
aa 91 (wild type/non-wild) 6/6 (50.00%/
50.00%)
5/2 (71.43%/28.57%) NS
aa 70 and 91(double-wild type/non-
double-wild type)
3/9 (25.00%/
75.00%)
1/6 (14.29%/85.71%) NS
Number of ISDR substituions 0 (wild type) 8 (66.67%) 3 (42.86%) NS
1-3 (intermediate type) 4 (33.33%) 4 (57.14%) NS
Effect of previous IFN
therapy (non-SVR)
12 (100%) 7 (100%) NS
HCV, hepatitis C virus; CH-C, chronic hepatitis C; LC-C, liver cirrhosis type C; HCC, hepatocellular carcinoma; IFN, interferon; SVR, sustained virological response;
ISDR, IFN sensitivity-determining region; NS, not significant
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Albumin
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